



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Oxaliplatin (Eloxatin®) in Metastatic Colorectal Cancer
(MCRC)
Capital District Health Authority/*Cancer Care Nova Scotia***

Approved Use:

Oxaliplatin: In **combination with 5-FU/LV infusional based chemotherapy (FOLFOX)** in patients who have documented evidence of **non-resectable locally advanced or MCRC**, as a first line **or** second line option, have an ECOG performance status of 0-2, for whom the combination would be recommended and who choose to receive systemic chemotherapy.

- This policy recommendation represents a **new guideline document** and a restriction